PNC Financial (PNC) will kick-start this quarter’s bank earnings tomorrow at 6:45 AM ET and we are all ears with its top- and bottom-lines predicted to see year-over-year growth. We had earlier reported that banks are entering this earnings season with numerous tailwinds in the form of corporate tax cut, higher employment rate, robust trading activity and a hike in interest rates. And PNC is one of better stocks that are likely to outperform in the first quarter.
In the previous four quarters, the financial services company has surprised the street by reporting higher earnings, which helped the stock outperform the one-year industry average gain of 21.8%, by reporting over 32% growth. This quarter, the company is expected to report a mid-single digit growth in revenue to about $4.16 billion, while earnings are estimated to be around $2.43 per share, driven by lower effective tax rates.
Meanwhile, organic growth is also a strong point for PNC, especially due to loan growth spurred by higher consumer confidence. The Federal Reserve’s decision to increase interest rates as well as higher underwriting fees due to active M&A environment will complement PNC’s ongoing cost-optimization measures in boosting organic growth.
Net interest income for the quarter is predicted to grow high-single-digit to $2.34 billion as the Fed rate hikes expand the interest rate margin.
This quarter, the company is expected to report a mid-single digit growth in revenue to about $4.16 billion, while earnings are estimated to be around $2.43 per share, driven by lower effective tax rates.
PNC’s strong point, its loan balance growth, has been the primary driving factor behind its solid performances in the trailing quarters. In the fourth quarter, the Pittsburg-based company posted 5% improvement in loan balances, commercial and consumer combined. The company anticipates another mid-single-digit increase in 2018 and we have no reason to doubt this figure, given the positive environment.
With PNC stock having an impressive growth of 30% in the past one year, we are not sure if the stock is set for another earnings beat. But positive fundamentals and a favorable market environment make the stock one of the better picks.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on